A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss

Xueling Wang,1–3,* Yuming Chen,1–3,* Yong Tao,1–3 Yunge Gao,1–3 Dehong Yu,1–3 Hao Wu1–3 1Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang XL, Chen YM, Tao Y, Gao YG, Yu DH, Wu H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	A666 peptide dexamethasone prestin cisplatin ototoxicity Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b2923a63c49e4e12a60c031902ce802b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b2923a63c49e4e12a60c031902ce802b
record_format	dspace
spelling	oai:doaj.org-article:b2923a63c49e4e12a60c031902ce802b2021-12-02T07:35:17ZA666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss1178-2013https://doaj.org/article/b2923a63c49e4e12a60c031902ce802b2018-11-01T00:00:00Zhttps://www.dovepress.com/a666-conjugated-nanoparticles-target-prestin-of-outer-hair-cells-preve-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Xueling Wang,1–3,* Yuming Chen,1–3,* Yong Tao,1–3 Yunge Gao,1–3 Dehong Yu,1–3 Hao Wu1–3 1Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Ear Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 3Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: The delivery of treatment agents to inner ear with drug delivery system (DDS) has been under investigation to overcome the limitations of the conventional therapeutic agents in curing or alleviating the cisplatin ototoxicity.Methods: In the present study, a novel targeted dexamethasone (DEX)-loaded DDS, A666-DEX-NP, was constructed for prevention from cisplatin-induced hearing loss. A666-(CLEPRWGFGWWLH) peptides specifically bind to prestin, which is limited to the outer hair cells (OHCs). HEI-OC1 and cisplatin-treated guinea pigs (12 mg/kg, intraperitoneal) were used as in vitro and in vivo models for investigating the targeting and protective efficiency against cisplatin.Results: As expected, compared to A666-unconjugated nanoparticles (NP), A666-conjugated coumarin 6-labeled NP showed active targeting to OHCs. Furthermore, A666-coumarin 6-labeled NP could be significantly internalized by HEI-OC1 cells via the A666–prestin interaction. This facilitated the uptake of cells pretreated with A666-DEX-NP, followed by the cisplatin-treated group, which led to enhanced cell viability, reduced apoptotic properties, and decreased reactive oxygen species levels as compared to cells pretreated with DEX or DEX-NP, 4 hours in advance of cisplatin treatment. In cisplatin-treated guinea pigs, pretreatment with A666-DEX-NP effectively preserved OHCs and showed significant hearing protection at 4, 8, and 16 kHz as compared to pretreatment with saline, DEX, or DEX-NP formulation.Conclusion: This OHC-targeting DDS provides a novel strategy for DEX application that can be potentially used to combat cisplatin ototoxicity. Keywords: A666 peptide, dexamethasone, prestin, cisplatin ototoxicity Wang XLChen YMTao YGao YGYu DHWu HDove Medical PressarticleA666 peptidedexamethasoneprestincisplatin ototoxicityMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 7517-7531 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	A666 peptide dexamethasone prestin cisplatin ototoxicity Medicine (General) R5-920
spellingShingle	A666 peptide dexamethasone prestin cisplatin ototoxicity Medicine (General) R5-920 Wang XL Chen YM Tao Y Gao YG Yu DH Wu H A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss
description	Xueling Wang,1–3,* Yuming Chen,1–3,* Yong Tao,1–3 Yunge Gao,1–3 Dehong Yu,1–3 Hao Wu1–3 1Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Ear Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 3Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: The delivery of treatment agents to inner ear with drug delivery system (DDS) has been under investigation to overcome the limitations of the conventional therapeutic agents in curing or alleviating the cisplatin ototoxicity.Methods: In the present study, a novel targeted dexamethasone (DEX)-loaded DDS, A666-DEX-NP, was constructed for prevention from cisplatin-induced hearing loss. A666-(CLEPRWGFGWWLH) peptides specifically bind to prestin, which is limited to the outer hair cells (OHCs). HEI-OC1 and cisplatin-treated guinea pigs (12 mg/kg, intraperitoneal) were used as in vitro and in vivo models for investigating the targeting and protective efficiency against cisplatin.Results: As expected, compared to A666-unconjugated nanoparticles (NP), A666-conjugated coumarin 6-labeled NP showed active targeting to OHCs. Furthermore, A666-coumarin 6-labeled NP could be significantly internalized by HEI-OC1 cells via the A666–prestin interaction. This facilitated the uptake of cells pretreated with A666-DEX-NP, followed by the cisplatin-treated group, which led to enhanced cell viability, reduced apoptotic properties, and decreased reactive oxygen species levels as compared to cells pretreated with DEX or DEX-NP, 4 hours in advance of cisplatin treatment. In cisplatin-treated guinea pigs, pretreatment with A666-DEX-NP effectively preserved OHCs and showed significant hearing protection at 4, 8, and 16 kHz as compared to pretreatment with saline, DEX, or DEX-NP formulation.Conclusion: This OHC-targeting DDS provides a novel strategy for DEX application that can be potentially used to combat cisplatin ototoxicity. Keywords: A666 peptide, dexamethasone, prestin, cisplatin ototoxicity
format	article
author	Wang XL Chen YM Tao Y Gao YG Yu DH Wu H
author_facet	Wang XL Chen YM Tao Y Gao YG Yu DH Wu H
author_sort	Wang XL
title	A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss
title_short	A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss
title_full	A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss
title_fullStr	A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss
title_full_unstemmed	A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss
title_sort	a666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b2923a63c49e4e12a60c031902ce802b
work_keys_str_mv	AT wangxl a666conjugatednanoparticlestargetprestinofouterhaircellspreventingcisplatininducedhearingloss AT chenym a666conjugatednanoparticlestargetprestinofouterhaircellspreventingcisplatininducedhearingloss AT taoy a666conjugatednanoparticlestargetprestinofouterhaircellspreventingcisplatininducedhearingloss AT gaoyg a666conjugatednanoparticlestargetprestinofouterhaircellspreventingcisplatininducedhearingloss AT yudh a666conjugatednanoparticlestargetprestinofouterhaircellspreventingcisplatininducedhearingloss AT wuh a666conjugatednanoparticlestargetprestinofouterhaircellspreventingcisplatininducedhearingloss
_version_	1718399359872139264

A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss

Ejemplares similares